Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Economic burden and healthcare resource utilization
13 evidence topics · 13 sources
Annual direct medical costs of NAFLD in the United States, steady-state prevalence model
“We constructed a steady-state prevalence model to quantify this burden in the United States and Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are highest in patients aged 45-65. The burden is significantly higher when societal costs are included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lifetime direct costs of NASH and advanced NASH in US adults, Markov model, 2017
“We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018
“In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Mean annual cost per patient (SD) | Early fibrosis | Advanced fibrosis | USA |
|---|---|---|---|
| NASH-related direct medical (physician-reported, n = 2,604, 1,150, 1,221) | “€2,224 (19,956)”View highlighted excerpt for this quote | “€3,983 (23,788)”View highlighted excerpt for this quote | “€4,881 (42,077)”View highlighted excerpt for this quote |
| Total direct medical, NASH-related and non-NASH | “€3,883 (20,634)”View highlighted excerpt for this quote | “€6,727 (25,052)”View highlighted excerpt for this quote | “€7,258 (36,704)”View highlighted excerpt for this quote |
| Indirect (patient-reported, n = 546, 221, 97) | “€5,939 (15,989)”View highlighted excerpt for this quote | “€12,642 (21,813)”View highlighted excerpt for this quote | “€13,435 (29,493)”View highlighted excerpt for this quote |
Annual non-drug costs by fibrosis stage and liver health state in a US cost-effectiveness model, based on US estimates from the GAIN study
| Health state | Annual cost, base case | Lower value | Upper value |
|---|---|---|---|
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |
Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer
“Our study was conducted from a health-care payer perspective and included direct medical costs associated with each health state (Table 2), including inpatient and outpatient, medications, and procedures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Health state | Direct medical cost, 2025 USD per year, base value | Range |
|---|---|---|
| F0-1 | “500”View highlighted excerpt for this quote | “480–510”View highlighted excerpt for this quote |
| F2-3 | “1180”View highlighted excerpt for this quote | “640–1720”View highlighted excerpt for this quote |
| Compensated cirrhosis | “23,360”View highlighted excerpt for this quote | “18,210–28,510”View highlighted excerpt for this quote |
| Decompensated cirrhosis | “36,290”View highlighted excerpt for this quote | “30,190–42,390”View highlighted excerpt for this quote |
| Hepatocellular carcinoma | “85,840”View highlighted excerpt for this quote | “60,900–110,790”View highlighted excerpt for this quote |
All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020
“Adults with NASH were identified in the Veradigm Health Insights Electronic Health Record Database and linked Komodo claims data. The index date was the earliest coded NASH diagnosis between 1 January 2016 and 31 December 2020 with valid FIB-4 and ≥6 months of database activity and continuous enrollment pre- and post-index.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 6,743 qualifying patients, index FIB-4 was ≤0.95 for 2,345 patents, 0.95-2.67 for 3,289 patients, 2.67-4.12 for 571 patients, and >4.12 for 538 patients (mean age 55.8 years; 62.9% female).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean age, comorbidity burden, cardiovascular disease risk, and healthcare utilization increased with increasing FIB-4. Mean ± SD annual costs increased from $16,744±$53,810 to $34,667±$67,691 between the lowest and highest FIB-4 cohorts” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A one-unit increase in FIB-4 at index was associated with a 3.4% (95%CI: 1.7%-5.2%) increase in mean total annual cost and an 11.6% (95%CI: 8.0%-15.3%) increased likelihood of hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care costs after identification of FIB-4-defined F3 or F4 fibrosis in 251,725 commercially insured US adults with NAFLD or NASH, 2008 to 2016
“Using the Optum Research Database, a retrospective cohort study was conducted among 251,725 commercially insured adult patients with ≥1 NAFLD/NASH diagnosis from January 1, 2008, to August 31, 2016, and laboratory data required to calculate FIB‐4 scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of FIB‐4‐based F3 and F4 fibrosis was 0.40%‐2.72% and 1.03%‐1.61%, respectively. Almost 50% of patients identified with FIB‐4‐based F3 or F4 had type 2 diabetes, cardiovascular disease, or renal impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total all‐cause health care costs increased significantly from pre‐index to post‐index for patients with FIB‐4‐based F3 fibrosis across most criteria (17%‐29% increase) and patients with FIB‐4‐based F4 fibrosis across all criteria (47%‐48% increase). Inpatient costs were the primary drivers of this increment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual all-cause costs by advanced liver disease stage in 485,774 commercially insured US adults with NAFLD or NASH, 2016 US dollars
“Adult NAFLD/NASH patients were identified retrospectively from MarketScan Commercial claims (2006-2016). Following initial NAFLD/NASH diagnosis, advanced liver diseases were identified using the first diagnosis as their index date. Mean annual all-cause HRU and costs (2016 USD) were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the database, 485,774 NAFLD/NASH patients met eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with NAFLD/NASH without advanced liver diseases (adjusted costs: $23,860), the annual cost of CC, DCC, LT, and HCC were 1.22, 5.64, 8.27, and 4.09 times higher [adjusted costs: $29,078, $134,448, $197,392, and $97,563 (P<0.0001)]. Inpatient admissions significantly drove increasing HRU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inpatient and outpatient charges and payments in Medicare beneficiaries with NAFLD, with and without cirrhosis, 2010
“Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For inpatients, median total hospital charge was $36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($61,151 vs. $33,863 and $18,804 vs. $10,146, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For outpatients, median total charge was $9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($12,049 vs. $8,830 and $2,586 vs. $1,734, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys
“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 87 physicians and 429 individuals with MASH provided data. The impact of MASH on activities was greater in high-versus low-risk MASH (activity impairment score: high risk, 30.8%; low risk, 17%; p <0.001 across all risk categories). Overall work impairment scores were 18.8% in low-risk and 19.9% in high-risk MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis was funded by Eli Lilly and Company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and work impairment by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AFwC patients also experienced greater impairment while working compared with EFnoC patients (29.7 ± 26.5 [n = 35] vs. 16.1 ± 21.3 [n = 28], p = 0.0271).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, the overall hospitalization rate was low in the 12 months before data collection (mean: 0.1 ± 1.1 times). However, those with AFwC were significantly more likely to be hospitalized because MASH comorbidities compared with those with EFnoC (p <0.0001; Table S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled US health care costs averted by a hypothetical therapy halting fibrosis progression in MASLD with moderate to advanced fibrosis
“The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote